The objectives of this study were to evaluate the feasibility of gadofosveset-enhanced magnetic resonance angiography (MRA) of the thoracic vasculature in the equilibrium phase and to determine the impact of gadofosveset dose on imaging quality.
Thirty healthy volunteers were randomized to receive a dose of 0.03, 0.02, or 0.01 mmol/kg of gadofosveset for MRA at 3 T in the equilibrium phase. Two radiologists assessed the central veins, the pulmonary arteries, and the thoracic aorta. Quantitative assessments were also performed.
At 0.03 and 0.02 mmol/kg, all vessel segments were rated as adequate. At a dose of 0.01 mmol/kg, less than 10% of vascular segments were collectively rated as inadequate. The signal-to-noise ratio and contrast-to-noise ratio were significantly lower in all segments at 0.01 mmol/kg compared with higher doses.
Gadofosveset-enhanced MRA of the thoracic vessels in the equilibrium phase in healthy volunteers resulted in adequate vessel visualization, even when dose reduction was performed.
This trial was registered with clinicaltrials.gov, identifier NCT01431300.
From the *Department of Radiology, Duke University Medical Center, Durham, NC; and †Department of Radiology, University Hospital of Basel, Basel, Switzerland.
Received for publication February 27, 2013; accepted May 1, 2013.
Reprints: Charles Y. Kim, MD, Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710 (e-mail: firstname.lastname@example.org).
This investigator-initiated study was sponsored by Lantheus Medical Imaging, Billerica, MA.
C.Y.K. was a member of the Lantheus Medical Imaging Speaker Bureau. No other authors report any conflicts of interest.